Obesity hypertension: The rationale for renin-angiotensin system blockade

Hong Kong Medical Journal

Volumn 11, Issue 3, 2005, Pages 217-220

  Chan, N N ^a   Tong, P C Y ^b   Kong, A P S ^b   Chan, J C N ^b  

^a Qualigenics Diabetes Centre   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; IRBESARTAN; LEPTIN; LOSARTAN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAMIPRIL; RENIN; SODIUM; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; TRIACYLGLYCEROL; VALSARTAN;

ADRENERGIC SYSTEM; ARTERIAL PRESSURE; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HONG KONG; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LIFESTYLE; METABOLIC SYNDROME X; NONHUMAN; NOTE; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WEIGHT GAIN;

ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; INSULIN RESISTANCE; OBESITY; RENIN-ANGIOTENSIN SYSTEM;

EID: 20644437295     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (28)

1. Bergman RN, Van Gitters GW, Mittelman SD, et al. Central role of the adipocyte in the metabolic syndrome. J Investig Med 2001;49:119-26.
2. Iimura O. Insulin resistance and hypertension in Japanese. Hypertens Res 1996;19(Suppl 1):1S-8S.
3. Cress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-12.
4. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension 2001;37:250-4.
5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
6. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.
7. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
8. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
9. Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004;44:1175-80.
10. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
11. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
12. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995;25:893-7.
13. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005;45:9-14.
14. Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005;45:356-62.
15. Romero JC, Reckelhoff JF. State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999;34:943-9.
16. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens 2002;20:71-8.
17. Stebbins CL, Symons JD. Role of angiotensin II in hemodynamic responses to dynamic exercise in miniswine. J Appl Physiol 1995;78:185-90.
18. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001;14:103S-115S.
19. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
20. Schorr U, Blaschke K, Turan S, Distler A, Sharma AM. Relationship between angiotensin, leptin and blood pressure levels in young normotensive men. J Hypertens 1998;16:1475-80.
21. Shiuchi T, Cui TX, Wu L, et al. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 2002;40:329-34.
22. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the reninangiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76-81.
23. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9.
24. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43:993-1002.
25. Rosano GM, Vitale C, castiglioni C, Cornoldi A, Fini M, Raffaele S. Comparative effect of telmisartan and losartan on glucose metabolism in hypertensive patients with the metabolism syndrome. Circulation 2004;110(Supp III):606S.
26. Clemenz M, Frank J, Schupp M, Goebel M, Unger T, Kintscher U. The PPAR γ-activating ARB irbesartan stimulates expression of the insulin-signaling protein CAP and enhances insulin-induced glucose uptake. Circulation 2004;110(Suppl III):3850S.
27. Clasen R, Sprang C, Schupp M, et al. The angiotensin type 1 receptor blocker irbesartan induces adiponectin expression via PPAR γ-activation. Circulation 2004;110(Suppl III):3851S.
28. Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52-61.